BC
MRK icon

Bowman & Company’s Merck MRK Stock Holding History

Bowman & Company’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,769
Closed -$2.04M – 113
2025
Q1 		$2.04M Buy
22,769
+651
+3% +$60.8K 1% 28
2024
Q4 		$2.2M Sell
22,118
-1,851
-8% -$191K 1.14% 22
2024
Q3 		$2.72M Buy
23,969
+2,184
+10% +$259K 1.43% 19
2024
Q2 		$2.7M Buy
21,785
+2,208
+11% +$284K 1.56% 18
2024
Q1 		$2.58M Sell
19,577
-560
-3% -$69K 1.56% 17
2023
Q4 		$2.19M Buy
20,137
+1,139
+6% +$118K 1.53% 15
2023
Q3 		$1.96M Buy
18,998
+1,029
+6% +$111K 1.56% 15
2023
Q2 		$2.07M Buy
17,969
+896
+5% +$102K 1.57% 15
2023
Q1 		$1.82M Buy
17,073
+1,886
+12% +$204K 1.33% 17
2022
Q4 		$1.68M Buy
15,187
+1,087
+8% +$111K 1.31% 14
2022
Q3 		$1.21M Buy
14,100
+961
+7% +$85.8K 1.1% 20
2022
Q2 		$1.2M Buy
13,139
+2,314
+21% +$205K 1.05% 16
2022
Q1 		$888K Buy
10,825
+2,024
+23% +$160K 0.68% 26
2021
Q4 		$677K Buy
+8,801
New +$701K 0.52% 36

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bowman & Company's MRK Position: Q2 2025 in Review

Bowman & Company sold out of Merck (MRK) in Q2 2025, closing a stake of 22,769 shares — an estimated $2.04M sold.

Bowman & Company first reported a position in MRK in Q4 2021 and held it in 14 quarters. The position peaked at $2.72M in Q3 2024. 3,327 funds tracked by Wall St. Rank hold MRK as of Q2 2025.

  • Bowman & Company reported no remaining Merck position as of Q2 2025 after selling out during the quarter.
  • Bowman & Company sold 22,769 Merck shares in Q2 2025, an estimated $2.04M.
  • Bowman & Company first reported a position in Merck in Q4 2021 and held it in 14 quarters.
  • Bowman & Company's Merck position peaked at $2.72M in Q3 2024.
  • 3,327 funds tracked by Wall St. Rank held Merck as of Q2 2025.

Based on Bowman & Company's 13F filing for Q2 2025, filed 9 Jul 2025.